Integrated technology roadmapping in startups: a case study of an AgTech in the Cachaça industry

Companies develop strategies to describe where they want to go and how they will reach their destination. Business strategies are useful but may not be sufficiently detailed for areas of high importance, such as technology and innovation. In this paper we examined the effort of building a technology roadmap with an early growth stage company located in the state of São Paulo, Brazil. Roadmaps are easy to design yet flexible tools that can allow decision makers to explore a myriad of possible strategies. However, the challenges ahead for new companies facing uncertain growth scenarios demand that framework conditions be adequately addressed, and that innovation culture and technology management tools are integrated with the technology roadmapping strategy. Based on the empirical evidence collected from the startup studied, along with the literature and interviews with key stakeholders, this paper developed a pathway to support technology and innovation plans for startups going through similar growth stages and provides directions for future research in the area, given the scarcity of evidence available of new high-tech companies' efforts in planning and developing new products.

Integrated technology roadmapping in startups: a case study of an AgTech in the Cachaça industry

Companies develop strategies to describe where they want to go and how they will reach their destination. Business strategies are useful but may not be sufficiently detailed for areas of high importance, such as technology and innovation. In this paper we examined the effort of building a technology roadmap with an early growth stage company located in the state of São Paulo, Brazil. Roadmaps are easy to design yet flexible tools that can allow decision makers to explore a myriad of possible strategies. However, the challenges ahead for new companies facing uncertain growth scenarios demand that framework conditions be adequately addressed, and that innovation culture and technology management tools are integrated with the technology roadmapping strategy. Based on the empirical evidence collected from the startup studied, along with the literature and interviews with key stakeholders, this paper developed a pathway to support technology and innovation plans for startups going through similar growth stages and provides directions for future research in the area, given the scarcity of evidence available of new high-tech companies' efforts in planning and developing new products.(AU)

Incentives and challenges related to technological research and innovation within the Unified Health System in the Federal District of Brazil. / Incentivos e desafios relacionados à condução da pesquisa científica, tecnológica e de inovação no âmbito do Sistema Único de Saúde no Distrito Federal, Brasil.

This article analyzes the profile of research conducted in the Federal District of Brazil funded through public calls for proposals issued by the Research for the SUS Program: shared health management/Federal District (PPSUS/DF) and a research support program run by the Superior School of Health Sciences, maintained by the Health Sciences Teaching and Research Foundation (ESCS/FEPECS, acronym in Portuguese). A document analysis was undertaken of all research funded by the PPSUS/DF and ESCS/FEPECS's Research Support Program between 2008 and 2017 using the following variables: year, title, research themes of the National Agenda for Health Research Priorities (ANPPS, acronym in Portuguese), implementing organization, area of application of research, and amount of funding. PPSUS/DF funded 73 projects with a total investment of approximately R$8 million, while ESCS/FEPECS funded 85 projects with a total investment of R$2.3 million. This study provides a critical analysis of the research themes supported by ESCS/FEPECS and PPSUS/DF between 2008 and 2017. It is recommended that future calls for proposals should prioritize the three leading causes of death in the Federal District and the organization and evaluation of healthcare services.

O objetivo deste trabalho foi analisar o perfil das pesquisas científicas financiadas no Distrito Federal provenientes das chamadas públicas do Programa Pesquisa para o SUS: Gestão Compartilhada em Saúde (PPSUS/DF) e Programa de Fomento a Pesquisa Científica da ESCS/FEPECS, no período de 2008 a 2017. O estudo é analítico e documental, abrangendo o universo das pesquisas financiadas nesses dois Programas. As variáveis foram: ano, título, tema de pesquisa da Agenda Nacional de Prioridades de Pesquisas em Saúde (ANPPS), setor de aplicação, instituição e valor financiado. No período de 2008 a 2017, 73 projetos foram financiados pelos cinco editais do PPSUS/DF. O valor total foi de aproximadamente oito milhões de reais. Em relação à ESCS/FEPECS, entre 2008 a 2017, foram financiados 85 projetos pelos dez editais lançados. O valor total foi de 2,3 milhões de reais. Concluiu-se que o perfil das pesquisas científicas permitiu uma análise crítica das temáticas dos projetos. Recomenda-se que os próximos editais adotem como prioridade de pesquisa as três principais causas de óbitos, o processo de organização e avaliação de linhas de cuidados, serviços de saúde e redes de atenção.

Incentivos e desafios relacionados à condução da pesquisa científica, tecnológica e de inovação no âmbito do Sistema Único de Saúde no Distrito Federal, Brasil / Incentives and challenges related to technological research and innovation within the Unified Health System in the Federal District of Brazil

Resumo O objetivo deste trabalho foi analisar o perfil das pesquisas científicas financiadas no Distrito Federal provenientes das chamadas públicas do Programa Pesquisa para o SUS: Gestão Compartilhada em Saúde (PPSUS/DF) e Programa de Fomento a Pesquisa Científica da ESCS/FEPECS, no período de 2008 a 2017. O estudo é analítico e documental, abrangendo o universo das pesquisas financiadas nesses dois Programas. As variáveis foram: ano, título, tema de pesquisa da Agenda Nacional de Prioridades de Pesquisas em Saúde (ANPPS), setor de aplicação, instituição e valor financiado. No período de 2008 a 2017, 73 projetos foram financiados pelos cinco editais do PPSUS/DF. O valor total foi de aproximadamente oito milhões de reais. Em relação à ESCS/FEPECS, entre 2008 a 2017, foram financiados 85 projetos pelos dez editais lançados. O valor total foi de 2,3 milhões de reais. Concluiu-se que o perfil das pesquisas científicas permitiu uma análise crítica das temáticas dos projetos. Recomenda-se que os próximos editais adotem como prioridade de pesquisa as três principais causas de óbitos, o processo de organização e avaliação de linhas de cuidados, serviços de saúde e redes de atenção.

Abstract This article analyzes the profile of research conducted in the Federal District of Brazil funded through public calls for proposals issued by the Research for the SUS Program: shared health management/Federal District (PPSUS/DF) and a research support program run by the Superior School of Health Sciences, maintained by the Health Sciences Teaching and Research Foundation (ESCS/FEPECS, acronym in Portuguese). A document analysis was undertaken of all research funded by the PPSUS/DF and ESCS/FEPECS's Research Support Program between 2008 and 2017 using the following variables: year, title, research themes of the National Agenda for Health Research Priorities (ANPPS, acronym in Portuguese), implementing organization, area of application of research, and amount of funding. PPSUS/DF funded 73 projects with a total investment of approximately R$8 million, while ESCS/FEPECS funded 85 projects with a total investment of R$2.3 million. This study provides a critical analysis of the research themes supported by ESCS/FEPECS and PPSUS/DF between 2008 and 2017. It is recommended that future calls for proposals should prioritize the three leading causes of death in the Federal District and the organization and evaluation of healthcare services.

How health economic evaluation (HEE) contributes to decision-making in public health care: the case of Brazil.

The universal access to a health care system for the Brazilian population was established in 1990. Brazil is a country with no tradition in the production and use of health economic evaluation (HEE) to guide decision making in the public health system. It is only within the last two decades that HEEs using a microeconomic approach have appeared in the academic field. On a national level, HEE and Health Technology Assessment (HTA), in a wider sense, were first taken into account in 2003. Two policies deserve to be mentioned - (i) the regulation of medicines in the Brazilian market, and (ii) science, technology and innovation policy. The latter required the fostering of applied research to encourage the application of methods which employ systematic reviews and economic analyses of cost-effectiveness to guide the incorporation of technologies in the Brazilian health care system. The Ministry of Health has initiated the process of incorporating these new technologies on a federal level during the last ten years. In spite of the improvement of HEE methods at Brazilian universities and research institutes, these technologies have not yet reached the governmental bodies. In Brazil, the main challenge lies in the production, interpretation and application of HEE to all technologies within the access scheme(s), and there is limited capacity building. Setting priorities can be the solution for Brazil to be able to perform HEE for relevant technologies within the access scheme(s) while the universal coverage system struggles with a triple burden of disease.

Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil.

The prevailing model for encouraging innovation based on patents and market-oriented raises at least two economic and ethical issues: it imposes barriers on individuals and developing countries governments' access to medicines by defining prices that do not match their income, and the unavailability of new or appropriate products to address the health problems of these populations. In the last decade, this scenario has undergone some changes due to the emergence of new actors, the contribution of aid resources, the introduction to the market of new products against neglected diseases, the development of new governmental healthcare policies and research programs, etc. One example of such initiatives is the Fixed-Dose Artesunate Combination Therapy (FACT) project consortium, which brought together institutions with different natures from both the North and the South, for the development of two antimalarial fixed-dose combinations recommended by the WHO - artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ). This paper proposes to describe and analyze the ASMQ consortium, which is the result of a new pharmaceutical development approach, based on a different paradigm - needs-driven instead of market-driven -, collaborative, with strategic participation of institutions from the South, funded by alternative resources (public and philanthropic). Thus, it represents an interesting object of study for bioethical debates on intellectual property and innovation, and its analysis is justified in light of the current debate on ways of stimulating needs-driven pharmaceutical innovation.